Advertisement
Dr. Milne, 64, joined Rib-X's Board of Directors in January, 2004, and iscurrently a Venture Partner with Radius Ventures, LLC, a health and lifesciences venture capital firm based in New York. Dr. Milne, a Pfizer veteranof thirty-two years, covered all elements of biomedical innovation, spanningpositions including Corporate Senior Vice President with global responsibilityfor Human Health and Veterinary Research and Development and Executive VicePresident for Global Research and Development. During Dr. Milne's tenure from1993 to 2001 as President for global research and development, Pfizer'sresearch investment increased five-fold from $493 million to over $2.3billion; a number of significant products were developed; a substantialportfolio of collaborations with prominent biotechnology companies was built;and a broad array of important new pharmaceutical products and discoverytechnologies were introduced.
Advertisement
Susan Froshauer, Ph.D., President and Chief Executive Officer at Rib-X,commented, "George and I have a long history of working together that goesback to our Pfizer days and I look forward to a renewed collaboration thatwill join his experience, that comes from his decades of focus onpharmaceutical R&D, with those of my team. Rib-X is entering a criticalperiod, and with the added dimension of George's Executive Chairmanship I amconfident we will realize the clinical fruits of our investments in becoming aleader in translating a proprietary understanding of the ribosome intoimportant new drug candidates. Rib-X has had the great fortune to work with ateam of directors that has offered unparalleled guidance as we strive todevelop new classes of antibiotics that are able to address the growingchallenge of multi-drug resistant bacteria. We appreciate the important roleHarry has played in the growth and development of Rib-X. We continue in thistradition with Dr. George Milne."
"Rib-X is poised to become a leader in the antibiotic space," said Dr.Milne. "I was attracted to Rib-X by the outstanding quality of theirleadership team, the importance of their mission of discovering and developingnew therapies for life threatening, resistant bacterial infections, and theirproven ability to translate their structure-based drug design platform intodistinctive new antibiotics. These include two compounds in later stageclinical development -- delafloxacin (RX-3341), for complicated skin and skinstructure infections and radezolid (RX-1741), for community-acquired pneumoniaand uncomplicated skin and skin structure infections as well as two programswith promising leads including two entirely new families of antibiotics forserious gram negative infections. Both clinical programs will report phase 2data in the second half of the year. These compounds are a direct reflectionof the effectiveness of Rib-X's unique three-dimensional insight into thebacterial ribosome, and its translation into the development of whole familiesof newly designed antibiotics that address major medical needs. I look forwardto my continued work with Susan and the Rib-X team as they take the Companyand its programs to the next level."
Dr. Milne also serves on a variety of boards including boards of CharlesRiver Laboratories, Mettler-Toledo, BioStorage Technologies, Athersys,Resolvyx, the Mystic Aquarium and the New York Botanical Garden. Dr. Milnereceived a B.S. in Chemistry from Yale University and his Ph.D. in OrganicChemis
